Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia

Graham S. Erwin, Paul R. Crisostomo, Yue Wang, Meijing Wang, Troy A. Markel, Mike Guzman, Ian C. Sando, Rahul Sharma, Daniel R. Meldrum

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Background: Stem cell therapy is a promising treatment modality for injured cardiac tissue. A novel mechanism for this cardioprotection may include paracrine actions. Our lab has recently shown that gender differences exist in mesenchymal stem cell (MSC) paracrine function. Estrogen is implicated in the cardioprotection found in females. It remains unknown whether 17β-estradiol (E2) affects MSC paracrine function and whether E2-treated MSCs may better protect injured cardiac tissue. We hypothesize that E2-exposed MSCs infused into hearts prior to ischemia may demonstrate increased vascular endothelial growth factor (VEGF) production and greater protection of myocardial function compared to untreated MSCs. Materials and methods: Untreated and E2-treated MSCs were isolated, cultured, and plated and supernatants were harvested for VEGF assay (enzyme-linked immunosorbent assay). Adult male Sprague-Dawley rat hearts (n = 13) were isolated and perfused via Langendorff model and subjected to 15 min equilibration, 25 min warm global ischemia, and 40 min reperfusion. Hearts were randomly assigned to perfusate vehicle, untreated male MSC, or E2-treated male MSC. Transcoronary delivery of 1 million MSCs was performed immediately prior to ischemia in experimental hearts. Results: E2-treated MSCs provoked significantly more VEGF production than untreated MSCs (933.2 ± 64.9 versus 595.8 ± 10.7 pg/mL). Postischemic recovery of left ventricular developed pressure was significantly greater in hearts infused with E2-treated MSCs (66.9 ± 3.3%) than untreated MSCs (48.7 ± 3.7%) and vehicle (28.9 ± 4.6%) at end reperfusion. There was also greater recovery of the end diastolic pressure with E2-treated MSCs than untreated MSCs and vehicle. Conclusions: Preischemic infusion of MSCs protects myocardial function and viability. E2-treated MSCs may enhance this paracrine protection, which suggests that ex vivo modification of MSCs may improve therapeutic outcome.

Original languageEnglish (US)
Pages (from-to)319-324
Number of pages6
JournalJournal of Surgical Research
Issue number2
StatePublished - Apr 1 2009


  • cardioprotection
  • estrogen
  • paracrine
  • sex hormones
  • VEGF

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia'. Together they form a unique fingerprint.

Cite this